A new type of engineered immune cell is showing promise in fighting cancer. This innovation works similarly to existing CAR-T-cell therapies but without the downside of suppressing the immune system, which can lead to serious infections.
CAR-T-cell therapy is a treatment where a patient’s T cells, a kind of immune cell, are modified to target cancer cells. They do this by producing proteins called chimeric antigen receptors (CARs) that specifically look for antigens on cancer cells. Until now, the most common target has been the CD19 molecule.
Scientists have now created a new version called CART4-34. This therapy targets B cell receptors associated with the gene IGHV4-34, which is often found in aggressive forms of cancer. Research shows that CART4-34 is as effective as traditional CD19 therapies at killing cancer cells in modified mice with diffuse large B cell lymphoma, but it spares healthy B cells.
Andrea Henden, a clinician–researcher from QIMR Berghofer Medical Research Institute in Australia, highlights a major issue with conventional CAR-T therapies. “When we destroy cells that express CD19, we also weaken the immune system,” she explains. This can make patients vulnerable to infections after treatment, which is a core concern.
The positive news doesn’t stop there. The engineered T cells could also be used to help treat autoimmune diseases, such as lupus. Marco Ruella from the University of Pennsylvania points out that antibodies targeting the IGHV4-34 gene are commonly found in lupus patients, especially those with more severe disease. This opens up possibilities for broader applications of this technology in medicine.
In 2022, a study indicated that around 1.5 million Americans suffer from lupus. As the understanding of immune responses evolves, treatments like CART4-34 may offer new hope. It’s a reminder of how closely intertwined cancer and autoimmune responses can be.
Overall, the development of CART4-34 marks a significant step forward in both cancer treatment and the management of autoimmune diseases. Researchers continue to explore the potential of engineered immune cells, aiming for safer and more effective therapies that transform patient outcomes.
For more detailed information on CAR-T cell therapies and current research, check sources like National Cancer Institute.
Source link
Cancer,Diseases,Medical research,Science,Humanities and Social Sciences,multidisciplinary
